GT Biopharma GTBP 深 沪
已收盘 09-19 16:00:00 美东时间
0.7821
-0.034
-4.12%
华盛通- 最 高0.8307
- 今 开0.83
- 成交量 25.40万股
- 最 低 0.78
- 昨 收 0.8157
- 总市值 278.23万
- 52周最高 4.10
- 市盈率 静 --
- 换手率 7.14%
- 52周最低 0.6303
- 委 比 76.99%
- 总股本 355.75万
- 历史最高 591.99
- 量 比 0.97
- 振 幅 6.22%
- 历史最低 0.6303
- 每 手 1
- 风险率 0.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多GT Biopharma Reports Reduced Losses Amid Ongoing Challenges
Gt Biopharma, Inc. ( ($GTBP) ) has released its Q2 earnings. Here is a breakdow...
09-05 11:51
GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GT Biopharma's Michael Breen will participate in the H.C. Wainwright Global Investment Conference on Sept 8-10, 2025 in NYC. A webcast of their presentation will be available starting Sept 5. The company continues to enroll patients in its GTBP-3650 Phase 1 trial for CD33-expressing hematologic malignancies and expects to release initial data later this year. GTB-5550 TriKE® IND submission for B7H3-positive solid tumors is on track for Q4 2025.
09-04 11:00
GT Biopharma Renews CEO Michael Breen’s Contract
An update from GT Biopharma ( ($GTBP) ) is now available. On August 26, 2025, G...
08-30 04:55
GT Biopharma Q2 EPS $(0.55) Beats $(0.68) Estimate
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.68) by 19.12 percent. This is a 74.65 percent increase over losses of $(2.17) per share from the
08-15 04:42
GT Biopharma Reports Second Quarter 2025 Financial Results
GT Biopharma, Inc. reported that its GTB-3650 TriKE® Phase 1 trial has completed dosing for Cohort 1 and 2, treating four patients, and has advanced into Cohort 3. Initial Phase 1 data is expected in late 2025. The company anticipates submitting an IND application for GTB-5550 in Q4 2025. As of June 30, 2025, GT Biopharma had $5.3 million in cash, sufficient to fund operations into Q1 2026. The company noted a decrease in R&D and SG&A expenses, r...
08-14 20:05
GT Biopharma Initiated Dosing In Cohort 3 Of Its Phase 1 Dose Escalation Trial Of GTB-3650 For Relapsed Or Refractory CD33 Expressing Hematologic Malignancies, Plans On Releasing Initial Phase 1 Results Later In 2025 Following Completion Of Additional Dose Cohorts
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed.The company plans
08-11 19:14
GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
GT Biopharma announced the initiation of Cohort 3 in its Phase 1 trial for GTB-3650, its second-generation TriKE therapy for treating relapsed or refractory CD33+ hematologic malignancies. Cohorts 1 and 2 were successfully completed with no safety issues, and the first patient in Cohort 3 has completed the first week of treatment. Early results from Cohorts 1 and 2 show promising immune activity, with NK cell activation and expansion observed. Th...
08-11 11:00
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Mustang Bio (NASDAQ:MBIO) stock increased by 217.6% to $3.78 during Mo...
07-08 01:06
GT Biopharma Appoints New Member to its Board of Directors
GT Biopharma appoints David C. Mun-Gavin to its Board of Directors. Mun-Gavin, a seasoned executive with global experience in private banking and oil trading, brings valuable insights as the company prepares for clinical data readouts and pipeline expansion. GT Biopharma focuses on immuno-oncology therapeutics using its proprietary TriKE® NK cell engager platform.
06-13 13:00
GT Biopharma Expands Convertible Preferred Stock Offering
GT Biopharma ( ($GTBP) ) has provided an update. On May 12, 2025, GT Biopharma,...
05-28 04:55
